(WO200259084) The present invention provides pharmaceutical compositions for inhibiting and treating diseases associated with ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase.
(WO200259084) What is claimed is: A compound represented by the formula: wherein A is a nitrogen- , oxygen- , or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; B is hydrogen, or a halogen, amino, or thiol group; C is hydrogen, or a halogen, amino, or thiol group; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon- , nitrogen- , or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon- , nitrogen- , or sulfur-substituted pyrophosphodiester bridge. 2. The compound of Claim 1, wherein A is an N-linked aryl or heterocyclic group. 3. The compound of Claim 2, wherein A is a nicotinamide group, a pyridyl group, a substituted pyridyl group, a pyrimidyl group, or a substituted pyrimidyl group. 4. The compound of Claim 3, which is a nicotinamide 2'- deoxyriboside. 5. The compound of Claim 3, which is β-l'-nicotinamide-2'- deoxyribose, β-D-l'-nicotinamide-2'-deoxyribofuranoside, β-l'-pyridyl-2'- deoxyribose, or 5'-phospho-l'-pyridyl-deoxyribose. 6. The compound of Claim 1, wherein A is an O-linked aryl or heterocyclic group having the formula -O-Y, wherein Y is an aryl or heterocyclic group. 7. The compound of Claim 6, wherein the aryl or heterocyclic group is a phenyl group, a substituted phenyl group, a pyridyl group, a substituted pyridyl group, or a pyrimidyl group. 8. The compound of Claim 1, wherein A is an S-linked aryl or heterocyclic group having the formula -S-Y, wherein Y is an aryl or heterocyclic group. 9. The compound of Claim 8, wherein the aryl or heterocyclic group is a phenyl group, a substituted phenyl group, a pyridyl group, a substituted pyridyl group, or a pyrimidyl group. 10. The compound of Claim 1, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen. 11. The compound of Claim 2, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen. 12. The compound of Claim 6, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen. 13. The compound of Claim 8, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen. 14. The compound of Claim 1, wherein D is a primary alcohol or hydrogen. 15. The compound of Claim 2, wherein D is a primary alcohol or hydrogen. 16. The compound of Claim 6, wherein D is a primary alcohol or hydrogen. 17. The compound of Claim 8, wherein D is a primary alcohol or hydrogen. 18. A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically-acceptable carrier. 19. A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically-acceptable carrier. 20. A pharmaceutical composition comprising the compound of Claim 6 and a pharmaceutically-acceptable carrier. 21. A pharmaceutical composition comprising the compound of Claim 8 and a pharmaceutically-acceptable carrier. 22. A method for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, comprising contacting the enzyme with an amount of the compound of Claim 1 effective to inhibit the enzyme. 23. A method for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, comprising contacting the enzyme with an amount of the compound of Claim 2 effective to inhibit the enzyme. 24. A method for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, comprising contacting the enzyme with an amount of the compound of Claim 6 effective to inhibit the enzyme. 25. A method for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, comprising contacting the enzyme with an amount of the compound of Claim 8 effective to inhibit the enzyme. 26. A method for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof, comprising administering to the subject the compound of Claim 1 in an amount effective to treat the disease or condition. 27. A method for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof, comprising administering to the subject the compound of Claim 2 in an amount effective to treat the disease or condition. 28. A method for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof, comprising administering to the subject the compound of Claim 6 in an amount effective to treat the disease or condition. 29. A method for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof, comprising administering to the subject the compound of Claim 8 in an amount effective to treat the disease or condition.
(WO200259084) LEGAL DETAILS FOR WO02059084 Actual or expected expiration date=2004-07-04 Legal state=DEAD Status=LAPSED Event publication date=2002-01-04 Event code=WO/APP Event indicator=Pos Event type=Examination events Application details Application country=WO WOUS0200371 Application date=2002-01-04 Standardized application number=2002WO-US00371 Event publication date=2002-08-01 Event code=WO/A2 Event type=Examination events International application published without international search report Publication country=WO Publication number=WO02059084 Publication stage Code=A2 Publication date=2002-08-01 Standardized publication number=WO200259084 Event publication date=2002-08-01 Event code=WO/AK Event indicator=Pos Event type=Designated states Designated states AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW Event publication date=2002-08-01 Event code=WO/AL Event indicator=Pos Event type=Designated states Designated countries for regional patents GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Event publication date=2003-05-22 Event code=WO/DFPE Event type=Examination events Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) Event publication date=2003-10-16 Event code=WO/A3 Event indicator=Pos Event type=Examination events Later publication of ISR with revised front page Publication country=WO Publication number=WO02059084 Publication stage Code=A3 Publication date=2003-10-16 Standardized publication number=WO200259084 Event publication date=2004-07-04 Event code=WO/EETL Event type=Event indicating Not In Force PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE AU2002246956 Actual or expected expiration date=2014-07-31 Legal state=DEAD Status=EXPIRED Corresponding cc: Designated or member state=AU Corresponding appl: AU2002246956 Application date in the designated or member state=2002-01-04 Application number in the designated or member state=2002AU-0246956 Corresponding cc: Designated or member state=AU Corresponding pat: AU2002246956 Publication stage code in the designated or member state=B2 Publication date in the designated or member state=2006-11-02 Publication number in the designated or member state=AU2002246956 Event publication date=2003-07-23 Event code=WO/WWE Event indicator=Pos Event type=Entry into national phase Wipo information: entry into national phase Corresponding cc: Designated or member state=AU Event publication date=2014-07-31 Event code=AU/STCHG Patent Status changed by the national office Corresponding cc: Designated or member state=AU LEGAL DETAILS FOR DESIGNATED STATE BG Actual or expected expiration date=2022-01-04 Legal state=ALIVE Status=PENDING Corresponding cc: Designated or member state=BG Corresponding appl: BG10801702 Event publication date=2003-07-22 Event code=WO/ENP Event type=Entry into national phase Entry into the national phase in: Corresponding cc: Designated or member state=BG LEGAL DETAILS FOR DESIGNATED STATE CA2433840 Actual or expected expiration date=2015-01-05 Legal state=DEAD Status=LAPSED Corresponding cc: Designated or member state=CA Corresponding appl: CA2433840 Application date in the designated or member state=2002-01-04 Application number in the designated or member state=2002CA-2433840 Corresponding cc: Designated or member state=CA Corresponding pat: CA2433840 Publication stage code in the designated or member state=A1 Publication date in the designated or member state=2002-08-01 Publication number in the designated or member state=CA2433840 Event publication date=2003-07-03 Event code=WO/WWE Event indicator=Pos Event type=Entry into national phase Wipo information: entry into national phase Corresponding cc: Designated or member state=CA Event publication date=2015-02-16 Event code=CA/STCHG Patent Status changed by the national office Corresponding cc: Designated or member state=CA LEGAL DETAILS FOR DESIGNATED STATE DE Actual or expected expiration date=2003-11-13 Legal state=DEAD Status=LAPSED Corresponding cc: Designated or member state=DE Event publication date=2003-11-13 Event code=WO/REG Event code=DE/8642 Event indicator=Neg Event type=Non-entry into national phase Event type=Event indicating Not In Force Reference to a national code Impact abolished for de - i.e. PCT appl. not ent. German phase Wirkung weggefallen fuer de Corresponding cc: Designated or member state=DE LEGAL DETAILS FOR DESIGNATED STATE EP1370139 Actual or expected expiration date=2014-08-22 Legal state=DEAD Status=LAPSED Corresponding cc: Designated or member state=EP Corresponding appl: EP02714706 Application date in the designated or member state=2002-01-04 Application number in the designated or member state=2002EP-0714706 Corresponding cc: Designated or member state=EP Corresponding pat: EP1370139 Publication stage code in the designated or member state=A2 Publication date in the designated or member state=2003-12-17 Publication number in the designated or member state=EP1370139 Event publication date=2002-09-25 Event code=WO/121 Event type=Designated states EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc: Designated or member state=EP Event publication date=2003-07-18 Event code=WO/WWE Event indicator=Pos Event type=Entry into national phase Wipo information: entry into national phase Corresponding cc: Designated or member state=EP Event publication date=2003-12-17 Event code=WO/WWP Event indicator=Pos Event type=Examination events Wipo information: published in national office Corresponding cc: Designated or member state=EP Event publication date=2015-02-11 Event code=EP/STCHG Patent Status changed by the national office Corresponding cc: Designated or member state=EP LEGAL DETAILS FOR DESIGNATED STATE JP Actual or expected expiration date=2006-03-27 Legal state=DEAD Status=LAPSED Corresponding cc: Designated or member state=JP Event publication date=2006-03-27 Event code=WO/NENP Event type=Event indicating Not In Force Non-entry into the national phase in: Corresponding cc: Designated or member state=JP Event publication date=2006-03-27 Event code=WO/WWW Event indicator=Neg Event type=Event indicating Not In Force Wipo information: withdrawn in national office Corresponding cc: Designated or member state=JP
最新评论
暂无评论。